EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

Journal for ImmunoTherapy of Cancer

ISSN 2051-1426 · BMJ

Neueste Artikel

  1. Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy

    Matthew P Zimmerman, Amy Y Huang, Emily K Cox, Rose Al Abosy, Wan Lin Chong, Alexander G Bastian, Katherine Vietor, Yacine A Choutri, Jenna L Collier, Vasyl Zhabotynsky, Haiyang Wang, Megan Fung, Siddharth Maruvada, Pristine C Onuoha, Sarah A Weiss, Emily J Robitschek, Jia-Ren Lin, Tuulia Vallius, Shishir M Pant, Peter K Sorger, Willy Hugo, Debattama R Sen, W Nicholas Haining, Arlene H Sharpe, Brian C Miller

    Erschienen: 2026-11DOI: 10.1136/jitc-2026-015096

  2. Integrating PET/CT and correlative biomarkers for prospective evaluation of extramedullary disease in relapsed/refractory B-ALL: implications for CAR T-cell therapy

    Mark L. Solter, Yannan J Wang, Grace Li, Fahmida Haque, Brynn B Duncan, Xiaolin Wu, Stephanie Harmon, Bonnie Yates, Dana Delgado Colon, Hao-Wei Wang, Constance M Yuan, Nisha Patel, Victoria M Giordani, Chloe M Sachs, Chloe N Hoang, John C Molina, Alexander W Rankin, Toni Foley, Casey Mcgrath, Flavia Gava, Chelsea Lamplugh, Alexandra Dreyzin, Sara K Silbert, Ismail Baris Turkbey, Esther Mena, Evrim B Turkbey, R Taylor Sundby, Nirali N Shah

    Erschienen: 2026-11DOI: 10.1136/jitc-2026-016031

  3. Integrated tumor and circulating immune profiling in the NEO-CESQ trial of perioperative cemiplimab for resectable cutaneous squamous cell carcinoma

    Paolo A Ascierto, Paolo Bossi, Mario Mandala, Paola Queirolo, Francesco Spagnolo, Franco Bassetto, Vittorio Rampinelli, Francesco Giovacchini, Paola Schiavo, Elisabetta Pennacchioli, Corrado Caracò, Giampiero Parrinello, Miriam Paone, Claudia Trojaniello, Elisabeth Livingstone, Dirk Schadendorf, Diana Giannarelli, Daniela Massi, Domenico Mallardo, Luisa Piccin

    Erschienen: 2026-11DOI: 10.1136/jitc-2026-016059

  4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0

    Yi Lin, Jack Aiello, David Avigan, Jesus G Berdeja, Yelak Biru, Ajai Chari, Lisa Hwa Christenson, Caitlin Costello, Alfred L Garfall, Damian J Green, Doris K Hansen, Sundar Jagannath, Amrita Krishnan, Shaji Kumar, Sagar Lonial, Nikhil C Munshi, Krina K Patel, Noopur Raje, Saad Z Usmani, Ravi Vij, Madhav V Dhodapkar

    Erschienen: 2026-11DOI: 10.1136/jitc-2026-016142

  5. Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy

    Victor Arias, James H Clubb, Tatiana V Kudling, Elise Jirovec, Santeri Artturi Pakola, Lyna Haybout, Dafne C A Quixabeira, Mirte van der Heijden, Nea Ojala, Susanna Grönberg-Vähä-Koskela, Sini Raatikainen, Michael J Chisamore, Katriina Jalkanen, Tuomo Alanko, Jukka Kemppainen, Maria Hellesuo, Anniina Färkkilä, Matthew Stephen Block, Tine Juul Monberg, Inge Marie Svane, Johanna Mäenpää, Suvi Sorsa, Claudia Kistler, João Manuel dos Santos, Anna Kanerva, Otto Hemminki, Victor Cervera-Carrascon, Akseli Hemminki

    Erschienen: 2026-11DOI: 10.1136/jitc-2026-016430

  6. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2 -deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma

    Alexander K Tsai, Meagan R Rollins, Madeline A Ellefson, Zoe C Schmiechen, Adam L Burrack, Ayaka Hulbert, Guhan Qian, Hongrong Zhang, Eduardo Cruz-Hinojoza, Jonah Z Butler, Jason S Mitchell, Olivia C Ghirardelli Smith, Stephen D O’Flanagan, Jenny Krause, Grant H Hickok, Paolo P Provenzano, David Masopust, Sunil R Hingorani, Philip D Greenberg, Ingunn M Stromnes

    Erschienen: 2026-10DOI: 10.1136/jitc-2026-015489

  7. Epigenetic repression of oncogenic signaling defines immune-permissive tumor states associated with response to immune checkpoint inhibitors in advanced NSCLC

    María Gallardo-Gómez, Uxía Termenón-Rivas, Irene Alonso-Álvarez, Martín Lázaro-Quintela, Caterina Aversa, Alejandro Francisco-Fernández, Maria Rodríguez-Rodríguez, Jenifer Brea, Sámer Abdulkader-Sande, Aitor Rodríguez-Casanova, Angel Díaz-Lagares, Samuel García, Mónica Martínez-Fernández

    Erschienen: 2026-10DOI: 10.1136/jitc-2026-015745

  8. Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy

    Lyna Haybout, Tatiana V Kudling, James H Clubb, Tine Juul Monberg, Benedetta Albieri, Santeri Artturi Pakola, Elise Jirovec, Victor Arias, Dafne C A Quixabeira, Susanna Juteau, Eva Ellebæk, Marco Donia, Rikke Løvendahl Eefsen, Troels Holz Borch, Torben Lorentzen, Helle Hendel, Cecilie Dam Vestergaard, Amir Khammari, Claudia Kistler, Marie Christine Wulff Westergaard, Özcan Met, Suvi Sorsa, Otto Hemminki, Anna Kanerva, Victor Cervera-Carrascon, Brigitte Dréno, Inge Marie Svane, Akseli Hemminki

    Erschienen: 2026-08DOI: 10.1136/jitc-2026-016003

Jahrgänge

2026 · 3862025 · 7042024 · 4792023 · 4762022 · 5682021 · 6202020 · 5642019 · 3572018 · 1592017 · 1032016 · 972015 · 5442014 · 4222013 · 318

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.